Bioequivalence and Bioavailability Forum 20:38 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

FDA Draft guidance on Good ANDA Submission Practices [Regulatives / Guidelines]

posted by BRB - Canada, 2018-01-03 21:42  - Posting: # 18137
Views: 768

Hi all,

The FDA just posted a draft guidance on Good ANDA submission practices:

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM591134.pdf


I found the section on deviations from product-specific guidances to be rather interesting such as:

A detailed justification for and data (such as their inclusion/exclusion criteria or demographic information) to support why their use of a particular study population does not affect their BE determination.

So for imatinib BE studies, which have been done in healthy subjects, but the guidance recommends to use patients, a detailed justification now needs to be provided?

BRB

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,783 posts in 4,003 threads, 1,258 registered users;
online 11 (0 registered, 11 guests [including 8 identified bots]).

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed